دورية أكاديمية
أعرض في EDS

Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women.

التفاصيل البيبلوغرافية
العنوان: Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women.
المؤلفون: Teo A; Department of Medicine and Radiology and Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia. andrew.teo@uqconnect.edu.au.; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Rockville, Maryland, USA. andrew.teo@uqconnect.edu.au., Randall LM; Department of Medicine and Radiology and Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.; Victoria Infectious Diseases Service, Peter Doherty Institute of Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia., Madanitsa M; College of Medicine, University of Malawi, Blantyre, Malawi.; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Mwapasa V; College of Medicine, University of Malawi, Blantyre, Malawi., Phiri LK; College of Medicine, University of Malawi, Blantyre, Malawi., Khairallah C; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Buffet C; Department of Medicine and Radiology and Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.; Victoria Infectious Diseases Service, Peter Doherty Institute of Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia., Karahalios A; Centre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia., Narum DL; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Rockville, Maryland, USA., Kuile FOT; Liverpool School of Tropical Medicine, Liverpool, UK., Rogerson SJ; Department of Medicine and Radiology and Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia. sroger@unimelb.edu.au.; Victoria Infectious Diseases Service, Peter Doherty Institute of Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. sroger@unimelb.edu.au.
المصدر: Scientific reports [Sci Rep] 2019 May 27; Vol. 9 (1), pp. 7878. Date of Electronic Publication: 2019 May 27.
نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Antimalarials/*therapeutic use , Artemisinins/*therapeutic use , Malaria, Falciparum/*drug therapy , Plasmodium falciparum/*drug effects , Pregnancy Complications, Parasitic/*drug therapy , Pyrimethamine/*therapeutic use , Quinolines/*therapeutic use , Sulfadoxine/*therapeutic use, Adolescent ; Adult ; Antibodies, Protozoan/immunology ; Drug Combinations ; Female ; Humans ; Malaria, Falciparum/diagnosis ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/immunology ; Malawi/epidemiology ; Mass Screening ; Plasmodium falciparum/immunology ; Plasmodium falciparum/isolation & purification ; Pregnancy ; Pregnancy Complications, Parasitic/diagnosis ; Pregnancy Complications, Parasitic/epidemiology ; Pregnancy Complications, Parasitic/immunology ; Young Adult
مستخلص: In a randomised trial comparing intermittent screening and treatment (IST) with dihydroartemisinin-piperaquine (DP) and intermittent preventive therapy against malaria in pregnancy (IPT) with sulfadoxine-pyrimethamine (SP) in Malawi, the impacts of IST-DP and IPT-SP on the development and maintenance of malaria antibody immunity were compared. Pregnant Malawian women were randomised to receive IST-DP or IPT-SP. In a nested study, paired enrolment and delivery plasma samples from 681 women were assayed for antibodies against recombinant antigens and for IgG and opsonising antibodies to antigens found on infected erythrocytes (IEs). At delivery, antibody responses did not differ between study arms. Between enrolment and delivery, antibodies to recombinant antigens decreased, whereas antibodies to IEs including opsonising antibodies remained stable. Overall, changes in antibody responses over pregnancy did not differ by treatment arm. Stratifying by gravidity, antibody to schizont extract decreased more in multigravidae receiving IST-DP than IPT-SP. There was minimal impact of treatment arm on the development and maintenance of malaria immunity. While antibodies to recombinant antigens declined between enrolment and delivery, antibodies directed against IEs tended to be more stable, suggesting longer-lasting protection.Clinical trial registration: Pa n African Clinical Trials Registry (PACTR201103000280319) 14/03/2011. URL: http://www.isrctn.com/ISRCTN69800930 .
References: Infect Immun. 2001 Dec;69(12):7487-92. (PMID: 11705924)
Infect Immun. 2014 Nov;82(11):4842-53. (PMID: 25156731)
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520. (PMID: 28289193)
Mol Microbiol. 2003 Jul;49(1):179-91. (PMID: 12823820)
BMJ. 1998 Apr 18;316(7139):1236-8. (PMID: 9553006)
Methods Mol Biol. 2015;1325:145-52. (PMID: 26450386)
Clin Infect Dis. 2018 Nov 28;67(12):1890-1896. (PMID: 29733338)
Infect Immun. 2004 Sep;72(9):5027-30. (PMID: 15321995)
J Infect Dis. 2012 Nov 15;206(10):1612-21. (PMID: 22966126)
Am J Trop Med Hyg. 2016 Mar;94(3):640-9. (PMID: 26711513)
Malar J. 2015 May 10;14:193. (PMID: 25957793)
J Infect Dis. 2011 Jul 1;204(1):27-35. (PMID: 21628655)
PLoS Med. 2016 Sep 13;13(9):e1002124. (PMID: 27622558)
PLoS One. 2013;8(2):e56183. (PMID: 23451036)
J Infect Dis. 2015 Jun 15;211(12):1997-2005. (PMID: 25564249)
Nature. 1998 Oct 29;395(6705):851-2. (PMID: 9804416)
PLoS One. 2012;7(6):e40049. (PMID: 22761948)
Lancet. 2004 Jan 24;363(9405):283-9. (PMID: 14751701)
Lancet Infect Dis. 2010 Jan;10(1):51-9. (PMID: 20129149)
Malar J. 2015 May 26;14:215. (PMID: 26006260)
Malar J. 2011 Feb 11;10:36. (PMID: 21314945)
J Clin Invest. 2012 Sep;122(9):3227-38. (PMID: 22850879)
J Infect Dis. 2014 Nov 1;210(9):1444-55. (PMID: 24799599)
Trends Parasitol. 2016 Nov;32(11):887-898. (PMID: 27546781)
Methods Mol Biol. 2015;1325:207-13. (PMID: 26450391)
J Infect Dis. 2010 May 1;201(9):1316-25. (PMID: 20350189)
Emerg Infect Dis. 2015 May;21(5):813-23. (PMID: 25898123)
J Infect Dis. 2001 Sep 1;184(5):618-26. (PMID: 11494167)
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):28-35. (PMID: 11425175)
سلسلة جزيئية: ISRCTN ISRCTN69800930
PACTR PACTR201103000280319
المشرفين على المادة: 0 (Antibodies, Protozoan)
0 (Antimalarials)
0 (Artemisinins)
0 (Drug Combinations)
0 (Quinolines)
37338-39-9 (fanasil, pyrimethamine drug combination)
6A9O50735X (artenimol)
88463U4SM5 (Sulfadoxine)
A0HV2Q956Y (piperaquine)
Z3614QOX8W (Pyrimethamine)
تواريخ الأحداث: Date Created: 20190529 Date Completed: 20201019 Latest Revision: 20210915
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6536723
DOI: 10.1038/s41598-019-44340-x
PMID: 31133672
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-019-44340-x